Evidence map›Paper›PMID 42682974›Full record

ArticlePNAS nexus2026

Host nucleolin-targeting unique peptide drugs as potent broad-spectrum anti-influenza therapies.

Thu Ha Nguyen, Muhammad Sharif, Jae-Hyun Kim, Yeong-Bin Baek, Mahmoud Soliman, Hyung-Jun Kwon, Seong-Hun Jeong, Ragab Farouk, Shaimaa Aboelmagd, Jae-Ha Ryu and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PNAS nexus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Thu Ha NguyenHost-Directed Antiviral Research Center, Chonnam National University, Gwangju 61186, South Korea.ORCID https://orcid.org/0000-0002-5322-7298
Muhammad SharifHost-Directed Antiviral Research Center, Chonnam National University, Gwangju 61186, South Korea.ORCID https://orcid.org/0000-0002-8500-3862
Jae-Hyun KimSchool of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 61005, South Korea.
Yeong-Bin BaekHost-Directed Antiviral Research Center, Chonnam National University, Gwangju 61186, South Korea.
Mahmoud SolimanDepartment of Pathology and Clinical Pathology, Faculty of Veterinary Medicine, Assiut University, Assiut 71526, Egypt.ORCID https://orcid.org/0000-0003-4110-3703
Hyung-Jun KwonHost-Directed Antiviral Research Center, Chonnam National University, Gwangju 61186, South Korea.
Seong-Hun JeongHost-Directed Antiviral Research Center, Chonnam National University, Gwangju 61186, South Korea.
Ragab FaroukHost-Directed Antiviral Research Center, Chonnam National University, Gwangju 61186, South Korea.ORCID https://orcid.org/0000-0002-9243-7335
Shaimaa AboelmagdHost-Directed Antiviral Research Center, Chonnam National University, Gwangju 61186, South Korea.
Jae-Ha RyuPilot Plant, HLB PEP, Gwangju Technopark, Gwangju 61008, South Korea.
Gyeong Min KimPilot Plant, HLB PEP, Gwangju Technopark, Gwangju 61008, South Korea.
Woonsung NaDepartment of Oral Microbiology and Immunology, and Dental Research Institute, School of Dentistry, Seoul National University, Seoul 03080, South Korea.
Don-Kyu KimHost-Directed Antiviral Research Center, Chonnam National University, Gwangju 61186, South Korea.ORCID https://orcid.org/0000-0002-6251-6438
Jeong-Sun KimHost-Directed Antiviral Research Center, Chonnam National University, Gwangju 61186, South Korea.ORCID https://orcid.org/0000-0003-4401-2890
Dong Ju LeeHost-Directed Antiviral Research Center, Chonnam National University, Gwangju 61186, South Korea.
Jae Il KimSchool of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 61005, South Korea.
Kyoung-Oh ChoHost-Directed Antiviral Research Center, Chonnam National University, Gwangju 61186, South Korea.ORCID https://orcid.org/0000-0002-5477-7021

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The persistent threat of influenza pandemics and seasonal outbreaks, coupled with rising resistance to existing antiviral drugs targeting influenza viruses, necessitates the development of new therapeutics. This study investigated the antiviral potential of cell-penetrating peptide-conjugated host nucleolin (NCL)-binding peptide drugs, AGM-380d (dimeric) and AGM-380t (tetrameric), as innovative, broad-spectrum host-directed anti-influenza therapies. Infection with both influenza A and B viruses (IAVs and IBVs) significantly increased NCL expression and colocalization with viral nucleoprotein (NP), a core component of viral ribonucleoprotein complexes, in both in vitro and in vivo settings. The peptide drugs rapidly localized to the nucleolus and specifically bound to NCL. This targeted binding successfully disrupted the interaction between NCL and the NP of IAV and IBV, effectively blocking nuclear NP trafficking and inhibiting the replication of both pandemic and seasonal strains. Importantly, AGM-380d and AGM-380t protected mice from lethal IAV challenge by markedly reducing lung viral replication and pathology. The combination of AGM-380t with oseltamivir resulted in 100% protection from mortality following the deadly IAV challenge. In conclusion, AGM-380d and AGM-380t are highly promising as novel, broad-spectrum host-directed antivirals for the management of seasonal and pandemic influenza.

Indexed as

AGM-380d and AGM-380tblockage of nucleoprotein traffickinghost-directed antiviralsinfluenzanucleolin

Identifiers

PMID42682974
PMCPMC13531714

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.